The University of North Carolina at Chapel Hill

The Florida State University Research Foundation, Inc.

Duke University

Other

Auburn University

US Government as Represented by the Secretary of the Army

Albert Einstein College of Medicine

The University of North Carolina at Charlotte

David W Boykin

Richard Ray Tidwell

W David Wilson

Christine C Dykstra

James E Hall

John R Perfect

Chad F Stephens

Arvind Kumar

Reto Brun

Mohamed A Ismail

Karl Werbovetz

Kenny V Brock

Reem K Arafa

Maurice Daniel Givens

David A Stringfellow

Arvid Kumar

Byron L Blagburn

M Syed Rahmathullah

Laixing Hu

Chad E Stephens

Iris Francesconi

Bijan P Das

Jaroslaw Spychala

Ulrich G Steidl

James C Hudson

Dennis E Kyle

Mariappan Anbazhagan

Gregory Poon

Sandra Ewald

James J Brendle

Iléana Anthony-Debré

Christopher A Rice

Abdelbasset A Farahat

Compounds, compositions, and methods for the treatment of infections caused byortrophozoites and/or cysts and for the disinfection of solids and/or liquids, such as medical and personal care items, for example contact lenses, that may harbortrophozoites and/or cysts are provided.

Treatment ofortrophozoites and/or cysts

Disclosed herein are inhibitors of PU.1. The inhibitors are useful for treating disorders associated with abnormal PU.1 levels and function.

PU.1 inhibitors

Novel aza analogues of dicationic terphenyl compounds for use in combating microbial infections are described. The compounds include those of Formula (III): wherein one of A, Y, and Zis N; Aris phenylene; and Aris a nitrogen-containing aromatic group. An exemplary compound of Formula (III) is: 

Substituted pyridines as antiparasitic AZA teraryl compounds

Novel aza analogues of dicationic terphenyl compounds for use in combating microbial infections are described. Also described are processes for synthesizing the compounds. The presently disclosed compounds can include those of the formulas:  Land Lare selected from the group consisting of: 

Linear dicationic terphenyls and their aza analogues as antiparasitic agents

Disclosed herein are novel dicationic teraryl compounds and their aza analogues, including compounds of Formula (IIe): wherein p and q are each 0 and each A, Y and Z is CR. An exemplary compound of Formula (IIe) is: Methods for combating microbial infections, such as parasiticspecies, with novel dicationic terphenyl compounds and their aza analogues are included. Processes for synthesizing novel dicationic terphenyl compounds and their aza analogues are disclosed along with methods for evaluation of the compounds as potential anti-protozoan agents.

Teraryl components as antiparasitic agents

Novel fused ring dicationic anti-protozoan compounds. Representative protozoan species include but are not limited to(T.b.r.) and. Prodrugs of these compounds can be used as an oral treatment for malaria and human African trypanosomiasis.

Fused ring dicationic anti-protozoan agents and their prodrugs

The present invention relates to novel 2,5-bis{[alkyl (or aryl) imino] aminophenyl}furans and thiophenes of the general formula in which R, R, Rand Rare each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups; Ris H, alkyl or aryl; Ris H, alkyl, aryl, or NRR, in which Rand Rare each independently selected from the group consisting of H, alkyl and aryl; and X is O, S or NR, in which Ris H or alkyl, and to the use of such compounds.

Synthesis and antimicrobial activity of novel dicationic 'reversed amidines'

Novel dicationic bichalcophene compounds are described. The presently disclosed novel dicationic bichalcophene compounds exhibit in vitro activity versus, orcomparable to that of pentamidine and furamidine. Some of the novel dicationic bichalcophene compounds displayed good activity in vivo in a murine model of ainfection.

Bichalcophenes and their prodrugs as antiprotozoal agents

A method for treating a microbial infection, including an infection from a protozoan pathogen, such asand, in a subject in need thereof by administering to the subject an effective amount of a dicationic imidazopyridine compound or a dicationic tetrahydro-imidazopyridine compound. Processes for synthesizing dicationic imidazopyridines and dicationic tetrahydro-imidazopyridines and the novel dicationic imidazopyridine and dicationic tetrahydro-imidazopyridine compounds themselves.

Dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents

The present invention relates to novel compounds and methods that are useful in treating members of the Flaviviridae family of viruses. Compounds of the present invention will have a structure according to Formulas (I)-(VI) as recited throughout the application.

Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection

A compound of Formula (I): wherein: wherein n is a number from 1 to 3, and Ris H or &#x2014;CONHRNRR, wherein Ris lower alkyl and Rand Rare each independently selected from the group consisting of H and lower alkyl.

Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents

The present invention relates to novel 2,5-bis{[alkyl (or aryl) imino]aminophenyl}furans and thiophenes of the general formula in which R, R, Rand Rare each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups; Ris H, alkyl or aryl; Ris H, alkyl, aryl, or NRR, in which Rand Rare each independently selected from the group consisting of H, alkyl and aryl; and X is O, S or NR, in which Ris H or alkyl, and to the use of such compounds.

The present invention relates to novel compounds and methods that are useful in treating members of the Flaviviridae family of viruses. Compounds of the present invention will have a structure according to Formulas (I)&#x2013;(VI) as recited throughout the application.

Growing community of inventors

Atlanta, GA, United States of America

David W Boykin